Literature DB >> 16723361

Does use of isotretinoin rule out a career in flying?

S P Mollan1, M Woodcock, R Siddiqi, J Huntbach, P Good, R A H Scott.   

Abstract

AIM: To evaluate whether previous isotretinoin use induces permanent, measurable, and clinically significant abnormalities in night vision such that flying is precluded, and whether potential military and civilian commercial aviators should be screened routinely.
METHODS: A retrospective, non-interventional, consecutive case series of 47 individuals with a confirmed history of oral isotretinoin use were compared to 20 age and sex matched controls.
RESULTS: 47 individuals (44 males and three females), age range 17-33, underwent Goldmann-Weekers dark adaptation (DA) and standard electroretinogram (ERG) according to ISCEV protocols. 34 patients showed no abnormality in any parameters. Two patients had abnormal DA and ERGs. The mean scotopic ERG b wave amplitude of the isotretinoin group was 496.5 microV (SD 51.3 microV) compared with 501.7 microV (62.3.1 microV) among the controls. The group mean a:b ratio was 0.55 (0.04) compared to 0.69 (0.08) in the controls.
CONCLUSION: Previous use of isotretinoin may have caused retinal toxicity in two subjects and laboratory evidence of night blindness in 11 further subjects. One subject had subclinical changes remaining in the ERG 96 months after cessation of isotretinoin. This may justify the directed use of electrophysiological screening in professions that are night vision critical.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723361      PMCID: PMC1857209          DOI: 10.1136/bjo.2006.092833

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Ocular side effects possibly associated with isotretinoin usage.

Authors:  F T Fraunfelder; F W Fraunfelder; R Edwards
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

2.  Guidelines for calibration of stimulus and recording parameters used in clinical electrophysiology of vision.

Authors:  Mitchell Brigell; Michael Bach; Colin Barber; Anne Moskowitz; John Robson
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

3.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

4.  Visual toxicity of synthetic retinoids.

Authors:  R D Brown; C E Grattan
Journal:  Br J Ophthalmol       Date:  1989-04       Impact factor: 4.638

5.  Abnormal retinal function associated with fenretinide, a synthetic retinoid.

Authors:  M I Kaiser-Kupfer; G L Peck; R C Caruso; M J Jaffe; J J DiGiovanna; E G Gross
Journal:  Arch Ophthalmol       Date:  1986-01

6.  Isotretinoin-associated intracranial hypertension.

Authors:  Frederick W Fraunfelder; Frederick T Fraunfelder; James J Corbett
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

Review 7.  Treatment of acne vulgaris.

Authors:  Aamir Haider; James C Shaw
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

Review 8.  Ocular side effects associated with isotretinoin.

Authors:  Frederick W Fraunfelder
Journal:  Drugs Today (Barc)       Date:  2004-01       Impact factor: 2.245

9.  Abnormal retinal function associated with isotretinoin therapy for acne.

Authors:  R G Weleber; S T Denman; J M Hanifin; W J Cunningham
Journal:  Arch Ophthalmol       Date:  1986-06

10.  Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy.

Authors:  P A Sieving; P Chaudhry; M Kondo; M Provenzano; D Wu; T J Carlson; R A Bush; D A Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

  10 in total
  3 in total

1.  Isotretinoin and night vision.

Authors:  S Pushpoth; S Sandramouli
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

2.  Dermatologists' Knowledge and Attitude Toward Isotretinoin Ocular Side Effects in Egypt.

Authors:  Mohammed Elshafie; Azza Srour; Hussien El-Ansarey; Mostafa Abdel-Kader; Ibrahim Kabbash; Mohamed Mashaly
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-09-18

Review 3.  Are we pharmacovigilant enough in ophthalmic practice?

Authors:  Ashok Dubey; Shailendra S Handu
Journal:  Indian J Ophthalmol       Date:  2013-05       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.